These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 12091334)
21. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466 [TBL] [Abstract][Full Text] [Related]
22. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174 [TBL] [Abstract][Full Text] [Related]
23. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440 [TBL] [Abstract][Full Text] [Related]
24. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Bar M; Flowers MED; Storer BE; Chauncey TR; Pulsipher MA; Thakar MS; Bethge W; Storb R; Maloney DG; Sandmaier BM Biol Blood Marrow Transplant; 2018 Feb; 24(2):308-313. PubMed ID: 29032276 [TBL] [Abstract][Full Text] [Related]
25. Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donors. Redei I; Langston AA; Lonial S; Cherry JK; Allen AJ; Hamilton E; Jones M; Bartlett VM; Waller EK Bone Marrow Transplant; 2002 Sep; 30(6):335-40. PubMed ID: 12235516 [TBL] [Abstract][Full Text] [Related]
27. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472 [TBL] [Abstract][Full Text] [Related]
28. Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies. Bhatnagar B; Rapoport AP; Fang HB; Ilyas C; Marangoz D; Akbulut V; Ruehle K; Badros A; Yanovich S; Akpek G Ann Hematol; 2014 Apr; 93(4):653-60. PubMed ID: 24097082 [TBL] [Abstract][Full Text] [Related]
29. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans. Maris M; Storb R Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197 [TBL] [Abstract][Full Text] [Related]
30. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907 [TBL] [Abstract][Full Text] [Related]
31. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Nagler A; Or R; Naparstek E; Varadi G; Slavin S Exp Hematol; 2000 Sep; 28(9):1096-104. PubMed ID: 11008023 [TBL] [Abstract][Full Text] [Related]
32. Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors. Shook DR; Triplett BM; Srinivasan A; Hartford C; Dallas MH; Pillai A; Laver J; Leung W Biol Blood Marrow Transplant; 2013 Feb; 19(2):291-7. PubMed ID: 23063628 [TBL] [Abstract][Full Text] [Related]
33. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521 [TBL] [Abstract][Full Text] [Related]
34. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Bensinger WI; Buckner CD; Shannon-Dorcy K; Rowley S; Appelbaum FR; Benyunes M; Clift R; Martin P; Demirer T; Storb R; Lee M; Schiller G Blood; 1996 Dec; 88(11):4132-8. PubMed ID: 8943847 [TBL] [Abstract][Full Text] [Related]